Category: Uncategorised

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses the outstanding PTX-100 Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’.

Stuart Roberts, co-founder and senior analyst at Pitt Street Research, outlined the recent Pitt Street Research report on Prescient Therapeutics.

Please join Prescient Therapeutics CEO James McDonnell for an investor briefing.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient CEO James McDonnell discusses why the First Patient Dosed marks a significant milestone in the commencement of the PTX-100 Phase 2a study, bringing a potential treatment one step closer to a current unmet need.

In this session MDF Global Managing Director Joe Webb discussed their plans to become possibly the largest exploration company on the planet within 5 years.

In this session Felix Gold Executive Director Joseph Webb discussed why the company holds what we believe to be the premier antimony asset in the United States.

In this session Prescient Therapeutics (ASX: PTX) CEO James McDonnell provides investors with a company update.

Please join Xsights Co-Founder and CEO Steve Wildisen for an investor briefing.

In this session Wellnex Life Managing Director Zack Bozinvoski discussed their game-changing deal with $60bn health giant Haleon.